Last 53,240
Change Today +790.00 / 1.51%
Volume 40.4K
PRGO On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
Frankfurt
As of 10:24 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Open
$53,080
Previous Close
$52,450
Day High
$53,370
Day Low
$52,930
52 Week High
03/6/14 - $58,780
52 Week Low
08/20/13 - $42,040
Market Cap
71.2B
Average Volume 10 Days
80.3K
EPS TTM
$3.41
Shares Outstanding
133.8M
EX-Date
06/1/14
P/E TM
45.9x
Dividend
$0.43
Dividend Yield
0.26%
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company Public Limited Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API) primarily in the United States, Israel, the United Kingdom, Mexico, and Australia. Its Consumer Healthcare business offers various OTC and nutrition products, including analgesics, cough and cold remedies, and gastrointestinal and feminine hygiene products, as well as vitamins, dietary supplements, and nutritional drinks. The company’s Nutritionals business develops, manufactures, markets, and distributes infant formula, pediatric nutritionals and vitamins, minerals, and supplements primarily under the Centrum, One-A-Day, Flintstones, and Osteo-Bi-Flex brands. Its Rx Pharmaceuticals business develops, manufactures, and markets a portfolio of generic prescription drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, and oral liquids and oral solid dosage forms. The company’s Active Pharmaceutical Ingredients (API) business develops, manufactures, and markets differentiated APIs and finished dosage forms for the branded and generic pharmaceutical industries. In addition, Perrigo Company Public Limited Company is developing TYSABRI for the treatment of multiple sclerosis and crohn’s disease; and ELND005 for the treatment of Alzheimer’s disease and bipolar disorder. Its Pharmaceutical and Medical Diagnostic Products business markets and manufactures branded prescription drugs under licenses; and imports other pharmaceutical and medical diagnostic products. The company sells its products to drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. Perrigo Company Public Limited Company was founded in 1887 and is headquartered in Dublin, Ireland.

9,900 Employees
Last Reported Date: 08/15/13
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $526.3K
Executive Vice President of Global Operations...
Total Annual Compensation: $452.5K
Executive Vice President, General Counsel and...
Total Annual Compensation: $452.5K
Executive Vice President and General Manager ...
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2013.

perrigo co plc (PRGO) Key Developments

Perrigo Reportedly Up For Sale

Perrigo Company Public Limited Company (NYSE:PRGO) has reportedly hired an investment bank to consider its sale through a merger with a major pharmaceutical firm, sourced informed. In response to the report, Perrigo said, "The company does not respond to rumors."

Perrigo Company Announces FDA Final Approval for the Store Brand Equivalent to Advil(R) Congestion Relief Tablets, 200 Mg/10 Mg

Perrigo Company announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil(R) Congestion Relief Tablets, 200 mg/10 mg. Perrigo expects to begin shipments of the product prior to the upcoming cough/cold/flu season. Advil(R) Congestion Relief Tablets, 200 mg/10 mg, (ibuprofen & phenylephrine hydrochloride tablets, 200 mg/10 mg) is indicated for the relief of sinus pressure, nasal swelling and congestion, and headache. Estimated annual sales of the product are approximately $18 million.

Perrigo Company Public Limited Company Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 10:00 AM

Perrigo Company Public Limited Company Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 10:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Joseph C. Papa, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:IT 53,240.00 +790.00

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 2,700 INR -33.60
Endo International PLC $70.27 USD +0.70
Hospira Inc $50.66 USD -0.12
Mead Johnson Nutrition Co $95.08 USD -0.34
Mylan Inc/PA $52.34 USD +0.28
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 85.6x
Price/Sales 5.3x
Price/Book 2.4x
Price/Cash Flow 108.4x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.